These findings are in line with previous studies from our laboratory demonstrating that high levels of CD157 expression can promote tumor cell survival and induce drug resistance in non-hematological tumors, namely epithelial ovarian cancer22,45 and malignant pleural mesothelioma23, eventually strengthening tumor aggressiveness. Here, BST1 is linked to neoplasm.